Harrow, Inc. Fair Value Assumptions, Expected Volatility Rate (Deprecated 2018-01-31)
Harrow, Inc. (HROW) reported Fair Value Assumptions, Expected Volatility Rate (Deprecated 2018-01-31) of 113.50% for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-08.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueAssumptionsExpectedVolatilityRate · last filed 2018-03-08
- Harrow, Inc. fair value assumptions, expected volatility rate (deprecated 2018-01-31) for fiscal 2017 was 113.50%, a 11.27% increase from fiscal 2016.
- Harrow, Inc. fair value assumptions, expected volatility rate (deprecated 2018-01-31) for fiscal 2016 was 102.00%.
| Period end | Fair Value Assumptions, Expected Volatility Rate (Deprecated 2018-01-31) 0 month | Fair Value Assumptions, Expected Volatility Rate (Deprecated 2018-01-31) 6 month | Fair Value Assumptions, Expected Volatility Rate (Deprecated 2018-01-31) 9 month | Fair Value Assumptions, Expected Volatility Rate (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2017-12-31 | 113.50% 10-K · filed 2018-03-08 | |||
| 2016-12-31 | 102.00% 10-K · filed 2018-03-08 | |||
| 2016-09-30 | 102.00% 10-Q · filed 2016-11-14 | |||
| 2016-06-30 | 102.00% 10-Q · filed 2016-08-15 | |||
| 2012-04-20 | 350.00% 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |